Overview

Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)

Status:
Completed

Trial end date:
2019-09-01

Target enrollment:

Participant gender:

Summary

The primary objective is to assess the effect of 2 dose levels of SNF472 (300 mg and 600 mg) compared to placebo on the progression of coronary artery calcium volume score over a 12-month (52 weeks) period in ESRD patients on HD

Phase:

Phase 2

Details

Lead Sponsor:

Laboratoris Sanifit
Sanifit Therapeutics S. A.

Collaborator:

Clinipace Worldwide